ATE542904T1 - Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen - Google Patents

Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen

Info

Publication number: ATE542904T1
Authority: AT; Austria
Prior art keywords: translational modifications; post; mammalian cells; present; proteinaceous molecules
Prior art date: 2001-10-29

Application number

AT02770322T

Other languages

English (en)

Inventor

Dirk Opstelten

Johan Kapteyn

Petrus Passier

Ronald Brus

Abraham Bout

Original Assignee

Crucell Holland Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-29

Filing date

2002-10-29

Publication date

2012-02-15

2001-10-29 Priority claimed from PCT/NL2001/000792 external-priority patent/WO2003050286A1/en

2002-04-19 Priority claimed from PCT/NL2002/000257 external-priority patent/WO2003089468A1/en

2002-10-29 Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE542904T1 publication Critical patent/ATE542904T1/de

Links

238000000034 method Methods 0.000 title abstract 4
102000004169 proteins and genes Human genes 0.000 title abstract 3
108090000623 proteins and genes Proteins 0.000 title abstract 3
238000012986 modification Methods 0.000 title 1
230000001323 posttranslational effect Effects 0.000 title 1
210000004962 mammalian cell Anatomy 0.000 abstract 5
230000004481 post-translational protein modification Effects 0.000 abstract 5
102000003951 Erythropoietin Human genes 0.000 abstract 3
108090000394 Erythropoietin Proteins 0.000 abstract 3
229940105423 erythropoietin Drugs 0.000 abstract 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 3
230000013595 glycosylation Effects 0.000 abstract 2
238000006206 glycosylation reaction Methods 0.000 abstract 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
229920001542 oligosaccharide Polymers 0.000 abstract 1
150000002482 oligosaccharides Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Virology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cardiology (AREA)
General Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)

AT02770322T 2001-10-29 2002-10-29 Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen ATE542904T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/NL2001/000792 WO2003050286A1 (en)	2001-10-29	2001-10-29	Methods and means for producing proteins with predetermined post-translational modifications
PCT/NL2002/000257 WO2003089468A1 (en)	2002-04-19	2002-04-19	Methods and means for producing proteins with predetermined post-translational modifications
PCT/NL2002/000686 WO2003038100A1 (en)	2001-10-29	2002-10-29	Methods and means for producing proteins with predetermined post-translational modifications

Publications (1)

Publication Number	Publication Date
ATE542904T1 true ATE542904T1 (de)	2012-02-15

Family

ID=26642018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02770322T ATE542904T1 (de)	2001-10-29	2002-10-29	Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen

Country Status (14)

Country	Link
US (3)	US7304031B2 (de)
EP (2)	EP2292770B1 (de)
JP (1)	JP4583029B2 (de)
CN (1)	CN100347306C (de)
AT (1)	ATE542904T1 (de)
AU (1)	AU2002335585B2 (de)
BR (1)	BR0213402A (de)
CA (2)	CA2465007C (de)
DK (1)	DK1440157T3 (de)
EA (2)	EA008220B1 (de)
ES (1)	ES2381104T3 (de)
IL (3)	IL161674A (de)
NO (1)	NO20042209L (de)
WO (1)	WO2003038100A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE445705T1 (de)	1995-06-15	2009-10-15	Crucell Holland Bv	Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US8236561B2 (en)	1999-04-15	2012-08-07	Crucell Holland B.V.	Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en)	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US20050164386A1 (en) *	1999-04-15	2005-07-28	Uytdehaag Alphonsus G.	Overexpression of enzymes involved in post-translational protein modifications in human cells
US7604960B2 (en)	1999-04-15	2009-10-20	Crucell Holland B.V.	Transient protein expression methods
US7297680B2 (en)	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7521220B2 (en)	1999-11-26	2009-04-21	Crucell Holland B.V.	Production of vaccines
US7192759B1 (en)	1999-11-26	2007-03-20	Crucell Holland B.V.	Production of vaccines
US7527961B2 (en)	1999-11-26	2009-05-05	Crucell Holland B.V.	Production of vaccines
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en)	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EA008220B1 (ru) *	2001-10-29	2007-04-27	Круселл Холланд Б.В.	Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
NZ533124A (en)	2001-12-07	2005-11-25	Crucell Holland B	Production of viruses, viral isolates and vaccines
US8524477B2 (en)	2002-10-29	2013-09-03	Crucell Holland B.V.	Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
AU2005223371B2 (en) *	2004-03-17	2011-06-09	Crucell Holland B.V.	Novel assay for the separation and quantification of hemagglutinin antigens
EP1844068A4 (de) *	2005-01-25	2009-09-30	Apollo Life Sciences Ltd	Moleküle und chimere moleküle davon
CN101247822B (zh) *	2005-06-01	2012-10-17	新潟Tlo株式会社	含有epo衍生物的血液相关疾病的治疗剂
AR053416A1 (es) *	2005-11-10	2007-05-09	Protech Pharma S A	Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
CA2628725A1 (en) *	2005-11-15	2007-05-31	Glycofi, Inc.	Production of glycoproteins with reduced o-glycosylation
US7642078B2 (en)	2005-12-28	2010-01-05	Crucell Holland B.V.	Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US20150038413A1 (en)	2006-02-03	2015-02-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en)	2006-02-03	2014-04-24	Prolor Biotech Ltd.	Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en)	2006-02-03	2015-02-03	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en)	2006-02-03	2019-07-16	Opko Biologics Ltd.	Methods of treatment with long-acting growth hormone
US7553941B2 (en) *	2006-02-03	2009-06-30	Modigene Inc	Long-acting polypeptides and methods of producing same
US10221228B2 (en)	2006-02-03	2019-03-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en)	2006-02-03	2016-02-02	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US8048849B2 (en)	2006-02-03	2011-11-01	Modigene, Inc.	Long-acting polypeptides and methods of producing same
WO2007098548A1 (en) *	2006-03-01	2007-09-07	Apollo Life Sciences Limited	A molecule and chimeric molecules thereof
WO2007142288A1 (ja)	2006-06-07	2007-12-13	The University Of Tokushima	エリスロポエチンを用いた虚血性疾患の治療
CN101505788B (zh)	2006-08-22	2013-06-26	中外制药株式会社	周围神经病变的预防和/或治疗药
AR065613A1 (es)	2007-03-09	2009-06-17	Chugai Pharmaceutical Co Ltd	Agentes de proteccion para organos transplantados
AU2008243007A1 (en) *	2007-04-16	2008-10-30	Momenta Pharmaceuticals, Inc.	Characterization of N-glycans using exoglycosidases
TWI488640B (zh)	2008-04-16	2015-06-21	菲瑞茵國際中心股份有限公司	藥學製劑
US8138092B2 (en)	2009-01-09	2012-03-20	Lam Research Corporation	Spacer formation for array double patterning
US9663778B2 (en)	2009-07-09	2017-05-30	OPKO Biologies Ltd.	Long-acting coagulation factors and methods of producing same
US12203113B2 (en)	2009-07-09	2025-01-21	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
TWI532495B (zh)	2009-10-05	2016-05-11	菲瑞茵國際中心股份有限公司	藥學製劑
CN103619358B (zh)	2011-03-31	2017-02-15	辉凌公司	药物制剂
WO2013067322A1 (en) *	2011-11-03	2013-05-10	Stc Biologics, Inc.	Method for determination of pharmacological properties of recombinant proteins
JP2015520128A (ja)	2012-04-19	2015-07-16	オプコバイオロジクスリミテッド	長時間作用性オキシントモジュリン変異体とその作製方法
US9790268B2 (en)	2012-09-12	2017-10-17	Genzyme Corporation	Fc containing polypeptides with altered glycosylation and reduced effector function
ES2882890T3 (es)	2012-11-20	2021-12-03	Opko Biologics Ltd	Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina
IL289918B2 (en)	2013-03-11	2025-07-01	Genzyme Corp	Site-specific antibody-drug conjugation through glycoengineering
US20150158926A1 (en)	2013-10-21	2015-06-11	Opko Biologics, Ltd.	Long-acting polypeptides and methods of producing and administering same
CA2954066A1 (en) *	2014-07-01	2016-01-07	Stc Biologics, Inc.	A method for development of recombinant proteins with fingerprint like similarity to the reference product
WO2016092550A2 (en)	2014-12-10	2016-06-16	Opko Biologics Ltd.	Methods of producing long acting ctp-modified polypeptides
EP3988113A1 (de)	2015-06-19	2022-04-27	OPKO Biologics Ltd.	Gerinnungsfaktoren mit langzeitwirkung und verfahren zur herstellung davon
BR112019000610A2 (pt)	2016-07-11	2019-07-02	Opko Biologics Ltd	fator vii de coagulação de longa ação e métodos de produção do mesmo
CA3026863A1 (en) *	2016-07-12	2018-01-18	Hexal Ag	Glycoprotein with reduced acetylation rate of sialic acid residues
US11124579B2 (en) *	2017-03-29	2021-09-21	Agency For Science, Technology And Research	Anti oligosaccharide antibody
WO2019075053A1 (en) *	2017-10-11	2019-04-18	Elanco Us Inc.	PORCINE G-CSF VARIANTS AND USES THEREOF
CN111514279B (zh) *	2020-06-16	2023-07-18	温州医科大学附属第二医院（温州医科大学附属育英儿童医院）	神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991005867A1 (en)	1989-10-13	1991-05-02	Amgen Inc.	Erythropoietin isoforms
US5789247A (en) *	1994-04-01	1998-08-04	Ballay; Annick	Expression in non-tumoral human lymphoblastoid lines with an integrative vector
ATE445705T1 (de)	1995-06-15	2009-10-15	Crucell Holland Bv	Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US6783980B2 (en) *	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2221819A1 (en) *	1997-03-27	1998-09-27	Thomas A. Gigliatti	Insect expression vectors
ATE290091T1 (de) *	1997-03-27	2005-03-15	Univ British Columbia	Insekten-expressionsvektoren
US6929946B1 (en) *	1998-11-20	2005-08-16	Crucell Holland B.V.	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
CZ20013695A3 (cs)	1999-04-13	2002-02-13	Kenneth S. Warren Laboratories	Farmaceutický prostředek
ES2237420T5 (es) *	1999-04-15	2010-03-03	Crucell Holland B.V.	Produccion de proteina recombinante en una celula humana.
US6855544B1 (en) *	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US7297680B2 (en) *	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) *	1999-04-15	2005-07-28	Uytdehaag Alphonsus G.	Overexpression of enzymes involved in post-translational protein modifications in human cells
US6913922B1 (en) *	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
FI109811B (fi) *	2000-09-26	2002-10-15	Medicel Oy	Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä
DE10056136A1 (de)	2000-11-07	2002-05-16	Nemod New Modalities	Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
US7473767B2 (en)	2001-07-03	2009-01-06	The Institute For Systems Biology	Methods for detection and quantification of analytes in complex mixtures
EP2305312B1 (de) *	2001-10-10	2015-03-04	ratiopharm GmbH	Neumodulierung und Glykokonjugation von Follitropin (FSH)
EA008220B1 (ru) *	2001-10-29	2007-04-27	Круселл Холланд Б.В.	Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
PT2314629E (pt) *	2002-07-18	2014-01-22	Merus B V	Produção recombinante de misturas de anticorpos
AU2005223371B2 (en) *	2004-03-17	2011-06-09	Crucell Holland B.V.	Novel assay for the separation and quantification of hemagglutinin antigens
US7183371B2 (en) *	2004-11-01	2007-02-27	General Electric Company	Method for making polycarbonate
US20080139608A1 (en) *	2006-12-06	2008-06-12	Universiteit Leiden	2,6,8, Trisubstituted 1-deazapurines and their different uses

2002
- 2002-10-29 EA EA200400605A patent/EA008220B1/ru not_active IP Right Cessation
- 2002-10-29 EP EP10177590.6A patent/EP2292770B1/de not_active Expired - Lifetime
- 2002-10-29 EP EP02770322A patent/EP1440157B1/de not_active Expired - Lifetime
- 2002-10-29 EA EA200602163A patent/EA012340B1/ru not_active IP Right Cessation
- 2002-10-29 WO PCT/NL2002/000686 patent/WO2003038100A1/en not_active Ceased
- 2002-10-29 CA CA2465007A patent/CA2465007C/en not_active Expired - Fee Related
- 2002-10-29 ES ES02770322T patent/ES2381104T3/es not_active Expired - Lifetime
- 2002-10-29 CA CA2756610A patent/CA2756610C/en not_active Expired - Fee Related
- 2002-10-29 CN CNB028216903A patent/CN100347306C/zh not_active Expired - Fee Related
- 2002-10-29 DK DK02770322.2T patent/DK1440157T3/da active
- 2002-10-29 US US10/494,140 patent/US7304031B2/en not_active Expired - Fee Related
- 2002-10-29 AU AU2002335585A patent/AU2002335585B2/en not_active Ceased
- 2002-10-29 BR BR0213402-0A patent/BR0213402A/pt not_active IP Right Cessation
- 2002-10-29 JP JP2003540365A patent/JP4583029B2/ja not_active Expired - Fee Related
- 2002-10-29 AT AT02770322T patent/ATE542904T1/de active
2004
- 2004-04-29 IL IL161674A patent/IL161674A/en not_active IP Right Cessation
- 2004-05-28 NO NO20042209A patent/NO20042209L/no not_active Application Discontinuation
2007
- 2007-01-24 US US11/657,202 patent/US7785833B2/en not_active Expired - Fee Related
- 2007-08-01 US US11/888,776 patent/US7696157B2/en not_active Expired - Fee Related
2009
- 2009-10-21 IL IL201674A patent/IL201674A/en not_active IP Right Cessation
- 2009-10-21 IL IL201673A patent/IL201673A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
EA012340B1 (ru)	2009-10-30
US20050164917A1 (en)	2005-07-28
US20070117742A1 (en)	2007-05-24
ES2381104T3 (es)	2012-05-23
CA2465007A1 (en)	2003-05-08
US7696157B2 (en)	2010-04-13
IL161674A (en)	2014-06-30
BR0213402A (pt)	2004-10-13
EP2292770A3 (de)	2012-12-19
CA2756610C (en)	2015-08-25
DK1440157T3 (da)	2012-05-07
JP4583029B2 (ja)	2010-11-17
CN100347306C (zh)	2007-11-07
EP2292770B1 (de)	2014-11-26
US7785833B2 (en)	2010-08-31
NO20042209L (no)	2004-07-28
EP2292770A2 (de)	2011-03-09
CA2465007C (en)	2012-01-17
IL201674A (en)	2013-10-31
AU2002335585B2 (en)	2007-08-16
JP2005507426A (ja)	2005-03-17
EA200602163A1 (ru)	2007-04-27
IL201673A (en)	2013-10-31
CN1578838A (zh)	2005-02-09
EA200400605A1 (ru)	2004-08-26
EP1440157A1 (de)	2004-07-28
US7304031B2 (en)	2007-12-04
EP1440157B1 (de)	2012-01-25
US20080032922A1 (en)	2008-02-07
EA008220B1 (ru)	2007-04-27
CA2756610A1 (en)	2003-05-08
WO2003038100A1 (en)	2003-05-08

Publication	Publication Date	Title
ATE542904T1 (de)	2012-02-15	Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
ATE405644T1 (de)	2008-09-15	Verfahren zur herstellung und reinigung von erythropoietin
DE59608743D1 (de)	2002-03-21	Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
DE69818865D1 (de)	2003-11-13	Verfahren zur herstellung von blockcopolymeren durch eine kontrollierte radikalpolymerisation mit dithioester
ATE91716T1 (de)	1993-08-15	Verfahren zur herstellung vielkettige polypeptide oder proteine.
DE69434578D1 (de)	2006-01-26	Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren
ATE500331T1 (de)	2011-03-15	Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
ATE405676T1 (de)	2008-09-15	Verfahren zur erzeugung doppelsträngiger dna mit einem 3'-einzelstranganteil und verwendungen dieser komplexe zur rekombination
DE69632887D1 (de)	2004-08-19	Verfahren zur zweckmässige Herstellung von Transglutaminase durch DNA-Rekombination
DE68928532D1 (de)	1998-02-12	Funktionelles, durch ein rekombinantes verfahren hergestelltes synthetisches proteinpolymer
ATE119198T1 (de)	1995-03-15	Verfahren zur herstellung von proteinen mittels rekombinanter dna.
DE60205624D1 (de)	2005-09-22	Methoden zur herstellung von im wesentlichen monodispersen polymermischungen mit polyethylenglykoleinheiten
ATE438722T1 (de)	2009-08-15	Verfahren zur herstellung von proteinen unter reduktion von mannosephosphat in der zuckerkette und dadurch hergestelltes glykoprotein
NO911688L (no)	1991-05-31	Neurotrophin-3, en ny neurotrofisk faktor relatert til neurovekstfaktor og hjerne-avledet neurotrofisk faktor.
HUP0100037A2 (hu)	2001-05-28	Genomiális eljárás segítségével azonosított fehérjék funkió szerinti osztályozására szolgáló nagy teljesítményű eljárás
KR910004803A (ko)	1991-03-29	간의 실질 세포 성장 인자, 이를 코딩하는 유전자, 이 인자를 생산하는 방법, 및 이 인자를 생산하는 형질전환체
ATE279441T1 (de)	2004-10-15	Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
ATE328102T1 (de)	2006-06-15	Verfahren zur herstellung von proteine
DE60122562D1 (de)	2006-10-05	Nukleinsäuren, die für stichodactylidae chromoproteine kodieren
ATE532793T1 (de)	2011-11-15	Verfahren zur herstellung von molekülen mit verminderter immunogenität
DE69902796D1 (de)	2002-10-10	Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DE69430975D1 (de)	2002-08-22	Verfahren zur Herstellung von Proteinen
DE59810914D1 (de)	2004-04-08	Verfahren zur herstellung von polymeren, die nucleobasen als seitengruppen aufweisen
EP1693380A3 (de)	2007-01-03	Nukleinsäuresequenz, die für das OPCA Gen kodiert
DE69901161D1 (de)	2002-05-08	Verfahren zur herstellung von mit polyazacycloalkanen gepropften kieselsäuregelen und deren verwendung